U.S. markets closed

Renalytix Plc (RNLX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.6000+0.0900 (+5.96%)
At close: 04:00PM EDT
1.5700 -0.03 (-1.87%)
After hours: 05:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close1.5100
Bid1.5500 x 800
Ask1.6700 x 1300
Day's Range1.5000 - 1.6456
52 Week Range1.0500 - 4.0380
Avg. Volume140,326
Market Cap76.016M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-1.1400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RNLX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Renalytix plc
    WD: Raising target price to $82.00WALKER & DUNLOP INC has an Investment Rating of HOLD; a target price of $82.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

    LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To

  • GlobeNewswire

    Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

    Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales EffortLONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the appointment of Howard Doran as Chief Business Officer, effective September 1, 2023. Mr. Doran’s primary resp

  • GlobeNewswire

    Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

    World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney diseaseLONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces the launch of its Clinical Advisory Board, a world-leading, multi-disciplinary clinical group, to help advance the use of FDA authorized kidneyintelX.dkd™ in mitigating uncontrolled kidney disease progression and guiding ea